Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1303P - Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Simon Baldacci

Citation

Annals of Oncology (2020) 31 (suppl_4): S754-S840. 10.1016/annonc/annonc283

Authors

S. Baldacci1, B. Besse2, V. Avrillon3, B. Mennecier4, P. Dubray-Longeras5, J. Mazieres6, R. Descourt7, M. Duruisseaux8, X. Quantin9, H. Doubre10, I. Monnet11, D. Moro-Sibilot12, S. Schneider13, S. Cousin14, P. Merle15, J. Otto16, A. Langlais17, F. Morin18, V. Westeel19, N. Girard20

Author affiliations

  • 1 Thoracic Oncology Department,, Lille University Hospital, 59020 - Lille/FR
  • 2 Dept Of Cancer Medicine, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 3 69, Centre Léon Bérard, 69008 - Lyon/FR
  • 4 Pathologie Respiratoire, C.H.U. Strasbourg-Nouvel Hopital Civil, 67000 - Strasbourg/FR
  • 5 Unité D'hospitalisation Du Département D'oncologie Médicale, Centre Jean Perrin, 63011 - Clermont-Ferrand/FR
  • 6 Thoracic Oncology Department, CHU Toulouse - Hôpital Larrey, 31059 - Toulouse/FR
  • 7 Medical Oncology, C.H.U. Brest - Hôpital Morvan, 29609 - Brest/FR
  • 8 Thoracic Oncology, Respiratory Department, Hôpital Louis Pradel-Hospices Civils de Lyon, 69500 - Bron/FR
  • 9 Medical Oncology, ICM Regional Cancer Institute of Montpellier, 34090 - Montpellier/FR
  • 10 Service De Pneumologie, Hopital Foch, 92151 - Suresnes/FR
  • 11 Hôpital De Jour De Pneumologie, CHI de Créteil,, Créteil/FR
  • 12 Thoracic Oncology, CHU de Grenoble, Hopital Michallon, 38700 - La Tronche/FR
  • 13 Service De Pneumologie, Centre Hospitalier de la Côte Basque, 64109 - Bayonne/FR
  • 14 Medical Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 15 Thoracic-oncology, CHU G-Montpied, 63011 - Clermont-Ferrand/FR
  • 16 Medicine, Centre Anticancer Antoine Lacassagne, 6100 - Nice/FR
  • 17 Biostatistics, IFCT, 75009 - Paris/FR
  • 18 Clinical Research Unit, French Cooperative Thoracic Intergroup, 75009 - Paris/FR
  • 19 Oncologie Thoracique Et Allergologie Respiratoire, CHRU Besancon - Hopital Jean Minjoz, 25030 - Besançon/FR
  • 20 Institut Du Thorax Curie-montsouris, Institut Curie, 75005 - Paris/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1303P

Background

Lorlatinib is a third-generation tyrosine kinase inhibitor (TKI) targeting ALK and ROS1. Lorlatinib has been made available in France from October 2015 through an EAP for advanced ALK+ NSCLC after failure of at least one ALK-TKI. Data regarding efficacy and safety of lorlatinib used in various ALK-TKI sequences are lacking despite the results of the landmark multi-cohort phase II trial.

Methods

All consecutive patients with advanced refractory ALK+ NSCLC enrolled in the French lorlatinib EAP from October 2015 to June 2019 were included. Data were collected from medical records. Primary endpoint was progression-free survival (PFS).

Results

197 patients were included: 112 (56.9%) women, 134 (69.1%) never-smokers, and 170 (86.3%) patients with stage IV disease at diagnosis. The most frequent histology was adenocarcinoma (93.4%). Median age was 60.6 years. At the time of initiation of lorlatinib, characteristics were the following: 152 (77.2%) patients had central nervous system (CNS) disease, 121 (72.9%) were PS0/1. Lorlatinib was delivered as 2nd/3rd/4th/5th+ line in 4.1%/18.3%/29.4%/48.2% of patients. 152 (77.2%) patients were previously treated with chemotherapy, 182 (92.4%) with crizotinib, 183 (92.9%) with a 2nd generation ALK-TKI. Median of follow up from lorlatinib intiation was 17.1 months (95%CI, 15.9-19.3). Median PFS and median overall survival from lorlatinib initiation were 9.72 months (95%CI, 5.95-11.96) and 32.92 months (95%CI, 18.73-NR), respectively. Median lorlatinib duration was 7.5 months (range: [0.2-37.9]). Overall response rate (ORR) and disease control rate were 50.6% (95%CI, 43.3% - 57.9%) and 86.7% (95%CI, 81.7% - 91.6%) respectively. CNS ORR was 42.9% (95%CI, 35.8% - 50.1%). 100 (50.8%) patients experienced tumor progression on lorlatinib. Treatment was stopped for treatment-related toxicity in 28 patients. The safety profile of lorlatinib was consistent with previously published data.

Conclusions

These real-life results show that lorlatinib NSCLC provides significant clinical benefit as well as a central nervous system anti tumoral activity in heavily pre-treated advanced ALK+ patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

IFCT.

Funding

Pfizer.

Disclosure

S. Baldacci: Honoraria (self): MSD; Honoraria (self): Boehringer Ingelheim; Travel/Accommodation/Expenses: Lilly; Travel/Accommodation/Expenses: GSK; Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: Pfizer; Research grant/Funding (institution): Merck. B. Besse: Research grant/Funding (institution): AbbVie, Amgen, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cristal Therapeutics, Daiichi Sankyo, Eli Lilly, GSK, Ignyta, Ipsen, Inivata, Janssen, Merck KGaA, MSD, Nektar, Onxeo, OSE Immunotherapeutics, Pfizer, PharmaMar. P. Dubray-Longeras: Research grant/Funding (institution): MSD. J. Mazieres: Advisory/Consultancy, Research grant/Funding (institution): Roche; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution): BMS; Advisory/Consultancy: MSD; Advisory/Consultancy: Pierre Fabre; Advisory/Consultancy: Hengrui; Advisory/Consultancy: Daiichi; Advisory/Consultancy: Boehringer; Advisory/Consultancy: Takeda. R. Descourt: Advisory/Consultancy: Takeda; Advisory/Consultancy: Roche; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: MSD; Advisory/Consultancy: BMS; Advisory/Consultancy: Novartis; Advisory/Consultancy: AstraZeneca. M. Duruisseaux: Advisory/Consultancy: Roche, BMS, AstraZeneca, MSD, Pfizer, AbbVie, Boehringer Ingelheim, Takeda; Research grant/Funding (institution): Nanostring, Blueprint, Pfizer, Takeda. X. Quantin: Travel/Accommodation/Expenses: Pfizer. D. Moro-Sibilot: Honoraria (self): BMS MSD Lilly Takeda Novartis Pfizer Roche AbbVie Boehringer AstraZeneca. V. Westeel: Speaker Bureau/Expert testimony: Roche, MSD, BMS; Honoraria (self): Roche; Advisory/Consultancy: BMS, AstraZeneca, Roche, Takeda; Research grant/Funding (institution): BMS, MSD, Roche, AbbVie, Merck Serono, Lilly, Fresenius; Travel/Accommodation/Expenses: Roche, Pfizer, BMS, Boehringer Ingelheim. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.